Global Exosome Technologies Market Size 2024, Forecast To 2033
6 Mar, 2024
The exosome technologies market has undergone exponential growth, escalating from $0.06 billion in 2023 to $0.07 billion in 2024, reflecting a compound annual growth rate (CAGR) of 26.7% during the historic period. This surge is attributed to therapeutic advancements, developments in isolation techniques, a boost in research funding, exploration in regenerative medicine, and the inception of clinical trials. Projecting into the future, the exosome technologies market is set for continued exponential growth, forecasting an increase to $0.18 billion in 2028, with a CAGR of 27.0%. The forecasted period is expected to witness sustained exponential growth driven by progress in regulatory frameworks, innovations in biomedical engineering, a proliferation of clinical trials, ongoing developments in regenerative medicine, and the integration of nanotechnology. Key trends in the forecast period include advancements in therapeutics, applications in diagnostics, the integration of nanotechnology, a surge in research funding, and ongoing developments in isolation techniques.
Global Exosome Technologies Market Key Driver
The rising prevalence of chronic diseases is expected to drive the growth of the exosome technologies market. Chronic disease refers to a health condition or disease that is persistent or long-lasting in its effects, usually lasting for three months or longer, and may get worse over time. The rising prevalence of chronic diseases demands exosome technologies that offer potential uses such as identifying disease-specific biomarkers and monitoring disease progression using exosome cargo analysis, targeted drug delivery, and immune modulation in chronic conditions. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based international resource for the scientific research community, the number of individuals aged 50 years and older having one or more chronic illnesses is projected to rise by 99.5%, reaching 142.66 million by 2050, up from 71.522 million in 2020 in the United States. Furthermore, in July 2022, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, approximately 47%, or 11.6 million individuals in Australia, were estimated to be affected by at least one of the ten chosen chronic ailments. Therefore, the rising prevalence of chronic diseases is expected to propel the growth of the exosome technologies market. In 2023, the exosome technologies market was valued at $X billion, and by 2024, it is projected to reach $Y billion. Looking ahead to 2028, the market size is anticipated to grow to $Z billion.
Get A Free Sample Of The Global Exosome Technologies Market ReportGlobal Exosome Technologies Market Segments
The exosome technologies market covered in this report is segmented –
1) By Exosome Type: Loaded Cargos, Non-Cargo
2) By Cell Source: HEK293 Cells, Mesenchymal Stem Cells (MSCs), Platelets, Erythrocytes, Natural Killer Cells, Other Cell Sources
3) By Application: Therapeutics, Diagnostics
4) By End-Users: Health Care Providers, Pharmaceutical And Biotechnology Companies, Other End-Users
By Geography:The regions covered in the exosome technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the exosome technologies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global exosome technologies market report during the forecast period. The regions covered in the exosome technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Exosome Technologies Industry Players
AEGLE Therapeutics, Aruna Bio Inc., Carmine Therapeutics Inc., Exosome Diagnostics Inc., Creative Biolabs Inc., Danaher Corporation, OmniSpirant Limited, Thermo Fisher Scientific Inc., Fujifilm Holdings Corporation, Anjarium Biosciences, NOVADIP Biosciences S.A., Exopharm Ltd., Organicell Regenerative Medicine Inc., Evox Therapeutics, Direct Biologics, ExoCan Healthcare Technologies Pvt. Ltd., ExoCoBio, ExonanoRNA LLC, ILIAS Biologics Inc., Illumina Inc., Invitrix Therapeutics, XOStem Inc., VivaZome Therapeutics Pty Ltd., Aethlon Medical Inc., Capricor Therapeutics, Codiak BioSciences, Exogenus Therapeutics, Exovita Biosciences, HansaBioMed Life Sciences, Hitachi Chemical Advanced Therapeutics Solutions
Get The Full Global Exosome Technologies Market Report
Exosome Technologies Market Overview
Exosome technologies refer to the use of exosomes, which are small extracellular vesicles of endosomal origin, in various fields such as regenerative medicine, biotechnology, and biomedical research. Exosome technology has potential applications in diagnostics, particularly in liquid biopsy-based diagnostics and biomarker discovery projects. Exosomes can be used as diagnostic biomarkers for the early detection of diseases.
Exosome Technologies Global Market Report 2023 provides data on the global exosome technologies market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The exosome technologies market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.